vTv Therapeutics Inc. (NASDAQ: VTVT) is a Healthcare company (Biotechnology) with a market capitalization of $68M. The Maz Rating grades it against the other companies in its sector.
vTv Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.29, vTv Therapeutics Inc. trades at 551.3x trailing earnings, 1.8x sales and 2.9x book value, with an EV/EBITDA of 1.2. Over the last twelve months it generated about $39M of revenue and $123997 of net income. It runs an operating margin of -29.8% and a net margin of -20.8%. It shows return on equity of -10.1%, return on invested capital of -15.3% and a free cash flow yield of -32.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 11.19. Over the past 52 weeks the share price ranged from $16.71 to $44.00, with a beta of 0.26.
vTv Therapeutics Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 7 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, vTv Therapeutics Inc. (VTVT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 21.6% / 30% · Interest income / Revenue 73400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 21.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 73400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 21.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 73400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 98.8% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 73400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 98.2% / 33.33% · (Cash+Recv) / Total Assets 98.2% / 33.33% · Interest income / Revenue 73400000.0% / 5% | Fail |
No. As of September 2026, vTv Therapeutics Inc. (VTVT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. vTv Therapeutics Inc. is over the AAOIFI limit on Interest income / Revenue.
About 73400000.0% of each dividend: vTv Therapeutics Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.